Free tool
FAERS Monitor: Elestrin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021813 or its brand name (Elestrin, Estradiol). Reports on generic versions are filed under their own applications.
Reports
46,961
Serious
0
0% of reports
Hospitalization
7,232
Death reported
909
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
Nothing to show.
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 524 |
| 2005 | 571 |
| 2006 | 402 |
| 2007 | 1,462 |
| 2008 | 428 |
| 2009 | 599 |
| 2010 | 954 |
| 2011 | 843 |
| 2012 | 1,139 |
| 2013 | 877 |
| 2014 | 1,113 |
| 2015 | 1,917 |
| 2016 | 2,350 |
| 2017 | 2,138 |
| 2018 | 2,487 |
| 2019 | 2,867 |
| 2020 | 2,875 |
| 2021 | 2,829 |
| 2022 | 3,051 |
| 2023 | 3,552 |
| 2024 | 3,700 |
| 2025 | 5,254 |
| 2026 | 5,027 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,007,198 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.